Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,018.39 -17.30 (-0.34%) Dow
37,903.29 +87.37 (+0.23%) Nasdaq
15,605.48 -52.34 (-0.33%) Bitcoin USD
57,661.13 +295.40 (+0.51%) CMC Crypto 200
1,248.64 -22.11 (-1.74%)
LLY Jun 2024 720.000 put
| Previous close | 9.48 |
| Open | 10.15 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 720.00 |
| Expiry date | 2024-06-21 |
| Day's range | 8.84 - 10.39 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Barrons.comNovo Nordisk Hikes Guidance as Weight-Loss Drug Sales Surge. Why the Stock’s Falling.
The Danish pharmaceutical giant, which became Europe’s most valuable company last year, said Wegovy sales jumped 106% in the first quarter.
- Reuters
UPDATE 6-Blockbuster obesity drug demand drives Novo Nordisk profit boost
Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly. Jyske Bank said the beat and upgrade were driven by a one-off U.S. sales adjustment, while underlying growth was a bit weaker than expected. Novo is currently the most valuable company in Europe by market capitalisation, worth some 540.4 billion euro ($576.44 billion) before Thursday's earnings, on the back of Wegovy's popularity.
ReutersBlockbuster obesity drug demand drives Novo Nordisk profit boost
Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly. Novo is currently the most valuable company in Europe by market capitalisation, worth some 540.4 billion euro ($576.44 billion) before Thursday's earnings, on the back of Wegovy's popularity.
